Literature DB >> 28656539

Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation.

Samantha B Schon1,2, Maren Shapiro3,4, Clarisa Gracia5, Suneeta Senapati5.   

Abstract

PURPOSE: The purpose of this study was to compare baseline characteristics and ovarian stimulation outcomes between patients presenting for medically indicated vs. elective fertility preservation consultation and to determine the impact of the 2013 ASRM guidelines on oocyte cryopreservation on the patient population presenting for fertility preservation consultation.
METHODS: Retrospective cohort study conducted at an academic center. Study population included 332 patients presenting for medically indicated fertility preservation consultation and 210 patients presenting for elective consultation.
RESULTS: Patients presenting for elective fertility preservation consultation were more likely to be of advanced age, non-Caucasian, highly educated, single, nulligravid, and meet criteria for diminished ovarian reserve (DOR). Additionally, patients presenting electively were more likely to have fertility insurance benefits. A higher percentage of patients with insurance benefits for oocyte cryopreservation proceeded to stimulation. There were no differences in stimulation parameters or number of retrieved oocytes between the groups when adjusted for age. Following release of the ASRM guidelines on oocyte cryopreservation, there was no difference in the percentage of patients in the medical group who proceeded with stimulation; however, a higher percentage of patients presenting electively underwent ovarian stimulation.
CONCLUSION: Although the populations presenting for medical compared with elective fertility preservation differ at baseline, ovarian stimulation parameters and outcomes are similar when adjusted for age. Insurance benefits for fertility preservation are not comprehensive and impact the decision to proceed with stimulation in all patients. The publication of the ASRM guidelines on oocyte cryopreservation increased utilization of this technology among patients presenting electively; however, they remained at an advanced age and with decreased ovarian reserve parameters.

Entities:  

Keywords:  ASRM guidelines; Fertility preservation; IVF; Oocyte cryopreservation

Mesh:

Year:  2017        PMID: 28656539      PMCID: PMC5581786          DOI: 10.1007/s10815-017-0968-5

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  36 in total

Review 1.  Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis.

Authors:  Shevach Friedler; Onder Koc; Yariv Gidoni; Arieh Raziel; Raphael Ron-El
Journal:  Fertil Steril       Date:  2011-11-10       Impact factor: 7.329

2.  Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment.

Authors:  Javier Domingo; Vicente Guillén; Yanira Ayllón; María Martínez; Elkin Muñoz; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Fertil Steril       Date:  2012-01-28       Impact factor: 7.329

3.  Addressing oncofertility needs: views of female cancer patients in fertility preservation.

Authors:  Samantha Yee; Kaajal Abrol; Melanie McDonald; Madeline Tonelli; Kimberly E Liu
Journal:  J Psychosoc Oncol       Date:  2012

4.  Does company-sponsored egg freezing promote or confine women's reproductive autonomy?

Authors:  Heidi Mertes
Journal:  J Assist Reprod Genet       Date:  2015-05-24       Impact factor: 3.412

5.  Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation.

Authors:  Kimberley A Hill; Tova Nadler; Rodica Mandel; Stephanie Burlein-Hall; Clifford Librach; Karen Glass; Ellen Warner
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

6.  Response to ovarian stimulation in patients facing gonadotoxic therapy.

Authors:  Lauren N C Johnson; Katherine E Dillon; Mary D Sammel; Brenda L Efymow; Monica A Mainigi; Anuja Dokras; Clarisa R Gracia
Journal:  Reprod Biomed Online       Date:  2013-01-19       Impact factor: 3.828

7.  Oocyte cryopreservation for social reasons: demographic profile and disposal intentions of UK users.

Authors:  Kylie Baldwin; Lorraine Culley; Nicky Hudson; Helene Mitchell; Stuart Lavery
Journal:  Reprod Biomed Online       Date:  2015-05-07       Impact factor: 3.828

Review 8.  Reproductive technology and the life course: current debates and research in social egg freezing.

Authors:  Kylie Baldwin; Lorraine Culley; Nicky Hudson; Helene Mitchell
Journal:  Hum Fertil (Camb)       Date:  2014-08-05       Impact factor: 2.767

Review 9.  Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.

Authors: 
Journal:  Fertil Steril       Date:  2016-09-24       Impact factor: 7.329

10.  Corporate giants provide fertility benefits: have they got it wrong?

Authors:  Miriam Zoll; Heidi Mertes; Janesh Gupta
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-10-30       Impact factor: 2.831

View more
  4 in total

1.  Factors Impacting Fertility Preservation in Adolescents and Young Adults with Cancer: A Retrospective Study.

Authors:  Erin M Mobley; Ginny L Ryan; Amy E Sparks; Varun Monga; William W Terry
Journal:  J Adolesc Young Adult Oncol       Date:  2019-10-25       Impact factor: 2.223

2.  Initiating patient discussions about oocyte cryopreservation: Attitudes of obstetrics and gynaecology resident physicians.

Authors:  B Peterson; C Gordon; J K Boehm; M C Inhorn; P Patrizio
Journal:  Reprod Biomed Soc Online       Date:  2018-11-07

Review 3.  Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation.

Authors:  Zachary Walker; Andrea Lanes; Elizabeth Ginsburg
Journal:  Reprod Biol Endocrinol       Date:  2022-01-07       Impact factor: 5.211

4.  Ten pathways to elective egg freezing: a binational analysis.

Authors:  Marcia C Inhorn; Daphna Birenbaum-Carmeli; Lynn M Westphal; Joseph Doyle; Norbert Gleicher; Dror Meirow; Martha Dirnfeld; Daniel Seidman; Arik Kahane; Pasquale Patrizio
Journal:  J Assist Reprod Genet       Date:  2018-08-03       Impact factor: 3.357

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.